Efficacy and safety of Micronized Purified
Efficacy and safety of Micronized Purified Flavonoid Fractions (MPFF) for the treatment of postoperative hemorrhoid complications.
The Hemorrhoidal Disease, a common anorectal disease, seriously affects patients’ quality of life. Micronized Purified Flavonoid Fractions (MPFF) have been shown to improve symptoms like pain or bleeding
The aim of this study was to evaluate the efficacy and safety of the Micronized Purified Flavonoid Fractions (MPFF) in treating postoperative hemorrhoid complications. The study design was a systematic review and meta-analysis of
existing literature on natural compounds for treating postoperative complications of hemorrhoids. A total of 22 randomized controlled trials (RCTs), including 2,335 participants were included in the analysis. Micronized Purified Flavonoid Fractions (MPFF) improved the clinical efficacy of post-hemorrhoidectomy and reduced the bleeding rate, pain score and edema score, although no substantial effect on adverse reactions was reported. Subgroup analyses showed a significant reduction in pain score and bleeding rate in trials with duration of 4–10 days and an improvement in clinical efficacy. Treatment for ≥ 10 days significantly improved the edema score; a dosage range of 1,800–2,700 mg/day of Micronized Purified Flavonoid Fractions (MPFF) significantly reduced edema and pain scores, whereas < 1,800 mg/day significantly improved clinical efficacy.So, based on searching the relevant literatures, this is the first meta-analysis on Micronized Purified Flavonoid Fractions (MPFF) treatment of postoperative hemorrhoid complications. Our findings suggest that Micronized Purified Flavonoid Fractions (MPFF) provide a reduction of postoperative hemorrhoid complications, and that dose and duration are key factors in its efficacy, as illustrated by subgroup analysis. Source: Haiqi Fu, Wenfang Guo, Baochang Zhou, Yibo Liu, Yuan Gao, Minhui Li, Alexander KIRIENKO, https://doi.org/10.1016/j.phymed.2022.154244
For More : click here
SCAC 06/22 DM 165 DAF – For the exclusive use of the health professional.
Keep up to date with our content
Subscribe to our newsletter so that you are always up to date with the news.